{
    "info": {
        "nct_id": "NCT04278768",
        "official_title": "A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome",
        "inclusion_criteria": "1. Males and females ≥18 years of age\n2. Life expectancy of at least 3 months\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤1\n4. Cytomorphology based confirmed diagnosis of MDS or AML (as per World Health Organisation [WHO] 2016 classification) with the following characteristics.\n\n   Phase 1 Dose Escalation (Monotherapy)\n\n   • AML (primary or secondary, including treatment-related) after failing at least 1 standard treatment (may include chemotherapy, re induction therapy or stem cell transplantation).\n\n   OR\n\n   • Higher-risk R/R MDS that are considered resistant/refractory following at least 2 to 3 cycles of hypermethylating agent (HMA) or evidence of early progression\n\n   Phase 2a Dose Expansion (Monotherapy)\n\n   Patients with:\n   * R/R AMLwith FLT3 mutations who have been previously treated with a FLT3 inhibitor\n   * R/R AML with spliceosome mutations of SF3B1 or U2AF1\n   * R/R hrMDS (IPSS-R score > 3.5) with spliceosome mutations of SF3B1 or U2AF1\n   * Number of pretreatments: 1 or 2\n5. Acceptable organ function at screening\n6. Ability to swallow and retain oral medications\n7. Negative serum pregnancy test in women of childbearing potential\n8. Women of childbearing potential and men who partner with a woman of childbearing potential must agree to use highly effective contraceptive methods for the duration of the study and for 90 days after the last dose of emavusertib\n9. Willing and able to provide written informed consent and comply with the requirements of the trial\n10. Able to undergo serial bone marrow sampling and peripheral blood sampling\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Diagnosed with acute promyelocytic leukemia (APL, M3)\n2. Has known active central nervous system (CNS) leukemia\n3. Allogeneic hematopoietic stem cell transplant (Allo-HSCT) within 60 days of the first dose of emavusertib, or clinically significant graft-versus-host disease (GVHD) requiring ongoing up titration of immunosuppressive medications prior to start of emavusertib\n4. Chronic myeloid leukemia (CML)\n5. Any prior systemic anti-cancer treatment such as chemotherapy, immunomodulatory drug therapy, etc., received within 3 weeks (or 5 half-lives) prior to start of emavusertib.\n\n   Localized radiation or surgical resection of skin cancers allowed.\n6. Use of any investigational agent within 3 weeks or 5 half-lives, whichever is shorter, prior to start of emavusertib\n7. Presence of an acute or chronic toxicity resulting from prior anti-cancer therapy, with the exception of alopecia that has not resolved to Grade ≤ 1within 7 days prior to start of emavusertib; presence of any acute or chronic non-hematological toxicity ≥ Grade 3 at Screening, or prior to start of emavusertib must resolve to ≤ Grade 2.\n8. Known allergy or hypersensitivity to any component of the formulation of emavusertib\n9. Major surgery, other than diagnostic surgery, <28 days from the start of emavusertib; minor surgery <14 days from the start of emavusertib\n10. Patients with active advanced malignant solid tumors\n11. Known to be human immunodeficiency virus (HIV) positive or have an acquired immunodeficiency syndrome-related illness\n12. Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) positive or Hepatitis C virus (HCV) infection <6 months prior to start of emavusertib unless viral load is undetectable, or HCV with cirrhosis\n13. Uncontrolled or severe cardiovascular disease including myocardial infarction or unstable angina within 6 months prior to CA-4948, New York Heart Association Class II or greater congestive heart failure, or left ventricular ejection fraction < 40% by echocardiogram or multi-gated acquisition scan, serious arrhythmias uncontrolled on treatment, clinically significant pericardial disease, cardiac amyloidosis, congenital long QT syndrome, or QTc with Fridericia's correction (QTcF) that is unmeasurable or > 450 milliseconds (msec) on Screening electrocardiogram (ECG)\n14. Gastrointestinal disease or disorder that could interfere with the swallowing, oral absorption, or tolerance of emavusertib\n15. Pregnant or lactating\n16. Systemic fungal, bacterial, viral, or other infection that is not controlled\n17. Any other severe, acute, or chronic medical, psychiatric or social condition, or laboratory abnormality that may increase the risk of trial participation or emavusertib administration",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "2. Life expectancy of at least 3 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of at least 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Phase 2a Dose Expansion (Monotherapy)",
            "criterions": [
                {
                    "exact_snippets": "Monotherapy",
                    "criterion": "therapy type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "monotherapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Acceptable organ function at screening",
            "criterions": [
                {
                    "exact_snippets": "Acceptable organ function at screening",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "acceptable"
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Ability to swallow and retain oral medications",
            "criterions": [
                {
                    "exact_snippets": "Ability to swallow",
                    "criterion": "swallowing ability",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "retain oral medications",
                    "criterion": "retention of oral medications",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Number of pretreatments: 1 or 2",
            "criterions": [
                {
                    "exact_snippets": "Number of pretreatments: 1 or 2",
                    "criterion": "number of pretreatments",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Males and females ≥18 years of age",
            "criterions": [
                {
                    "exact_snippets": "Males and females",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "≥18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Phase 1 Dose Escalation (Monotherapy)",
            "criterions": [
                {
                    "exact_snippets": "Phase 1 Dose Escalation (Monotherapy)",
                    "criterion": "trial phase",
                    "requirements": [
                        {
                            "requirement_type": "phase",
                            "expected_value": "1"
                        }
                    ]
                },
                {
                    "exact_snippets": "Phase 1 Dose Escalation (Monotherapy)",
                    "criterion": "treatment regimen",
                    "requirements": [
                        {
                            "requirement_type": "regimen type",
                            "expected_value": "monotherapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Negative serum pregnancy test in women of childbearing potential",
            "criterions": [
                {
                    "exact_snippets": "Negative serum pregnancy test in women of childbearing potential",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "women of childbearing potential",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive status",
                            "expected_value": "childbearing potential"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* R/R AML with spliceosome mutations of SF3B1 or U2AF1",
            "criterions": [
                {
                    "exact_snippets": "R/R AML",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": "relapsed or refractory"
                        }
                    ]
                },
                {
                    "exact_snippets": "spliceosome mutations of SF3B1 or U2AF1",
                    "criterion": "spliceosome gene mutation",
                    "requirements": [
                        {
                            "requirement_type": "gene",
                            "expected_value": [
                                "SF3B1",
                                "U2AF1"
                            ]
                        },
                        {
                            "requirement_type": "mutation status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Willing and able to provide written informed consent and comply with the requirements of the trial",
            "criterions": [
                {
                    "exact_snippets": "Willing ... to provide written informed consent",
                    "criterion": "written informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "comply with the requirements of the trial",
                    "criterion": "trial requirements compliance",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "• AML (primary or secondary, including treatment-related) after failing at least 1 standard treatment (may include chemotherapy, re induction therapy or stem cell transplantation).",
            "criterions": [
                {
                    "exact_snippets": "AML (primary or secondary, including treatment-related)",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "after failing at least 1 standard treatment (may include chemotherapy, re induction therapy or stem cell transplantation)",
                    "criterion": "prior standard treatment for AML",
                    "requirements": [
                        {
                            "requirement_type": "number of failed standard treatments",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* R/R AMLwith FLT3 mutations who have been previously treated with a FLT3 inhibitor",
            "criterions": [
                {
                    "exact_snippets": "R/R AML",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": "relapsed or refractory"
                        }
                    ]
                },
                {
                    "exact_snippets": "FLT3 mutations",
                    "criterion": "FLT3 mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previously treated with a FLT3 inhibitor",
                    "criterion": "prior FLT3 inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Able to undergo serial bone marrow sampling and peripheral blood sampling",
            "criterions": [
                {
                    "exact_snippets": "Able to undergo serial bone marrow sampling",
                    "criterion": "bone marrow sampling",
                    "requirements": [
                        {
                            "requirement_type": "ability to undergo procedure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "frequency",
                            "expected_value": "serial"
                        }
                    ]
                },
                {
                    "exact_snippets": "Able to undergo ... peripheral blood sampling",
                    "criterion": "peripheral blood sampling",
                    "requirements": [
                        {
                            "requirement_type": "ability to undergo procedure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "frequency",
                            "expected_value": "serial"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Cytomorphology based confirmed diagnosis of MDS or AML (as per World Health Organisation [WHO] 2016 classification) with the following characteristics.",
            "criterions": [
                {
                    "exact_snippets": "Cytomorphology based confirmed diagnosis of MDS or AML (as per World Health Organisation [WHO] 2016 classification)",
                    "criterion": "diagnosis of MDS or AML",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "cytomorphology"
                        },
                        {
                            "requirement_type": "classification system",
                            "expected_value": "World Health Organisation (WHO) 2016"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* R/R hrMDS (IPSS-R score > 3.5) with spliceosome mutations of SF3B1 or U2AF1",
            "criterions": [
                {
                    "exact_snippets": "R/R hrMDS",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "relapsed or refractory high-risk myelodysplastic syndrome"
                        }
                    ]
                },
                {
                    "exact_snippets": "IPSS-R score > 3.5",
                    "criterion": "IPSS-R score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">",
                                "value": 3.5,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "spliceosome mutations of SF3B1 or U2AF1",
                    "criterion": "spliceosome gene mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "SF3B1",
                                "U2AF1"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "• Higher-risk R/R MDS that are considered resistant/refractory following at least 2 to 3 cycles of hypermethylating agent (HMA) or evidence of early progression",
            "criterions": [
                {
                    "exact_snippets": "Higher-risk R/R MDS",
                    "criterion": "myelodysplastic syndrome (MDS)",
                    "requirements": [
                        {
                            "requirement_type": "risk level",
                            "expected_value": "higher-risk"
                        },
                        {
                            "requirement_type": "relapsed/refractory status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "considered resistant/refractory following at least 2 to 3 cycles of hypermethylating agent (HMA)",
                    "criterion": "response to hypermethylating agent (HMA)",
                    "requirements": [
                        {
                            "requirement_type": "resistant/refractory status after HMA",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of HMA cycles",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "cycles"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of early progression",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "early progression",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Women of childbearing potential and men who partner with a woman of childbearing potential must agree to use highly effective contraceptive methods for the duration of the study and for 90 days after the last dose of emavusertib",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential ... must agree to use highly effective contraceptive methods for the duration of the study and for 90 days after the last dose of emavusertib",
                    "criterion": "contraceptive use (women of childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraceptive method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration of contraception",
                            "expected_value": "for the duration of the study and for 90 days after the last dose of emavusertib"
                        }
                    ]
                },
                {
                    "exact_snippets": "men who partner with a woman of childbearing potential must agree to use highly effective contraceptive methods for the duration of the study and for 90 days after the last dose of emavusertib",
                    "criterion": "contraceptive use (men with partners of childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraceptive method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration of contraception",
                            "expected_value": "for the duration of the study and for 90 days after the last dose of emavusertib"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "9. Major surgery, other than diagnostic surgery, <28 days from the start of emavusertib; minor surgery <14 days from the start of emavusertib",
            "criterions": [
                {
                    "exact_snippets": "Major surgery, other than diagnostic surgery, <28 days from the start of emavusertib",
                    "criterion": "major surgery (other than diagnostic surgery)",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "minor surgery <14 days from the start of emavusertib",
                    "criterion": "minor surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Systemic fungal, bacterial, viral, or other infection that is not controlled",
            "criterions": [
                {
                    "exact_snippets": "Systemic fungal, bacterial, viral, or other infection that is not controlled",
                    "criterion": "systemic infection",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "fungal",
                                "bacterial",
                                "viral",
                                "other"
                            ]
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Chronic myeloid leukemia (CML)",
            "criterions": [
                {
                    "exact_snippets": "Chronic myeloid leukemia (CML)",
                    "criterion": "chronic myeloid leukemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Patients with active advanced malignant solid tumors",
            "criterions": [
                {
                    "exact_snippets": "active advanced malignant solid tumors",
                    "criterion": "malignant solid tumors",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Pregnant or lactating",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Use of any investigational agent within 3 weeks or 5 half-lives, whichever is shorter, prior to start of emavusertib",
            "criterions": [
                {
                    "exact_snippets": "Use of any investigational agent within 3 weeks or 5 half-lives, whichever is shorter, prior to start of emavusertib",
                    "criterion": "use of investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "recency of use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Known allergy or hypersensitivity to any component of the formulation of emavusertib",
            "criterions": [
                {
                    "exact_snippets": "Known allergy or hypersensitivity to any component of the formulation of emavusertib",
                    "criterion": "allergy or hypersensitivity to any component of the formulation of emavusertib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Known to be human immunodeficiency virus (HIV) positive or have an acquired immunodeficiency syndrome-related illness",
            "criterions": [
                {
                    "exact_snippets": "Known to be human immunodeficiency virus (HIV) positive",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have an acquired immunodeficiency syndrome-related illness",
                    "criterion": "acquired immunodeficiency syndrome (AIDS)-related illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Any other severe, acute, or chronic medical, psychiatric or social condition, or laboratory abnormality that may increase the risk of trial participation or emavusertib administration",
            "criterions": [
                {
                    "exact_snippets": "severe, acute, or chronic medical, psychiatric or social condition",
                    "criterion": "medical, psychiatric, or social condition",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "severe",
                                "acute",
                                "chronic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "laboratory abnormality",
                    "criterion": "laboratory abnormality",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Any prior systemic anti-cancer treatment such as chemotherapy, immunomodulatory drug therapy, etc., received within 3 weeks (or 5 half-lives) prior to start of emavusertib.",
            "criterions": [
                {
                    "exact_snippets": "Any prior systemic anti-cancer treatment such as chemotherapy, immunomodulatory drug therapy, etc., received within 3 weeks (or 5 half-lives) prior to start of emavusertib.",
                    "criterion": "prior systemic anti-cancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Allogeneic hematopoietic stem cell transplant (Allo-HSCT) within 60 days of the first dose of emavusertib, or clinically significant graft-versus-host disease (GVHD) requiring ongoing up titration of immunosuppressive medications prior to start of emavusertib",
            "criterions": [
                {
                    "exact_snippets": "Allogeneic hematopoietic stem cell transplant (Allo-HSCT) within 60 days of the first dose of emavusertib",
                    "criterion": "allogeneic hematopoietic stem cell transplant (Allo-HSCT)",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 60,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant graft-versus-host disease (GVHD) requiring ongoing up titration of immunosuppressive medications prior to start of emavusertib",
                    "criterion": "graft-versus-host disease (GVHD)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        },
                        {
                            "requirement_type": "immunosuppressive medication titration",
                            "expected_value": "ongoing up titration prior to start of emavusertib"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Diagnosed with acute promyelocytic leukemia (APL, M3)",
            "criterions": [
                {
                    "exact_snippets": "Diagnosed with acute promyelocytic leukemia (APL, M3)",
                    "criterion": "acute promyelocytic leukemia (APL, M3) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Has known active central nervous system (CNS) leukemia",
            "criterions": [
                {
                    "exact_snippets": "Has known active central nervous system (CNS) leukemia",
                    "criterion": "central nervous system (CNS) leukemia",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "awareness/diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) positive or Hepatitis C virus (HCV) infection <6 months prior to start of emavusertib unless viral load is undetectable, or HCV with cirrhosis",
            "criterions": [
                {
                    "exact_snippets": "Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) positive",
                    "criterion": "Hepatitis B virus (HBV) DNA",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hepatitis C virus (HCV) infection <6 months prior to start of emavusertib",
                    "criterion": "Hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "time since infection",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless viral load is undetectable",
                    "criterion": "viral load (HBV or HCV)",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "HCV with cirrhosis",
                    "criterion": "cirrhosis in HCV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Gastrointestinal disease or disorder that could interfere with the swallowing, oral absorption, or tolerance of emavusertib",
            "criterions": [
                {
                    "exact_snippets": "Gastrointestinal disease or disorder that could interfere with the swallowing, oral absorption, or tolerance of emavusertib",
                    "criterion": "gastrointestinal disease or disorder",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with swallowing, oral absorption, or tolerance of emavusertib",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Uncontrolled or severe cardiovascular disease including myocardial infarction or unstable angina within 6 months prior to CA-4948, New York Heart Association Class II or greater congestive heart failure, or left ventricular ejection fraction < 40% by echocardiogram or multi-gated acquisition scan, serious arrhythmias uncontrolled on treatment, clinically significant pericardial disease, cardiac amyloidosis, congenital long QT syndrome, or QTc with Fridericia's correction (QTcF) that is unmeasurable or > 450 milliseconds (msec) on Screening electrocardiogram (ECG)",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled or severe cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "uncontrolled or severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction or unstable angina within 6 months prior to CA-4948",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction or unstable angina within 6 months prior to CA-4948",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association Class II or greater congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "left ventricular ejection fraction < 40% by echocardiogram or multi-gated acquisition scan",
                    "criterion": "left ventricular ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "serious arrhythmias uncontrolled on treatment",
                    "criterion": "arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "seriousness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control on treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant pericardial disease",
                    "criterion": "pericardial disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac amyloidosis",
                    "criterion": "cardiac amyloidosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "congenital long QT syndrome",
                    "criterion": "congenital long QT syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "QTc with Fridericia's correction (QTcF) that is unmeasurable or > 450 milliseconds (msec) on Screening electrocardiogram (ECG)",
                    "criterion": "QTc with Fridericia's correction (QTcF)",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 450,
                                "unit": "milliseconds"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Localized radiation or surgical resection of skin cancers allowed.",
            "criterions": [
                {
                    "exact_snippets": "Localized radiation ... allowed",
                    "criterion": "localized radiation for skin cancers",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "surgical resection of skin cancers allowed",
                    "criterion": "surgical resection of skin cancers",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Patients with:",
            "criterions": []
        },
        {
            "line": "OR",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "7. Presence of an acute or chronic toxicity resulting from prior anti-cancer therapy, with the exception of alopecia that has not resolved to Grade ≤ 1within 7 days prior to start of emavusertib; presence of any acute or chronic non-hematological toxicity ≥ Grade 3 at Screening, or prior to start of emavusertib must resolve to ≤ Grade 2.",
            "criterions": [
                {
                    "exact_snippets": "Presence of an acute or chronic toxicity resulting from prior anti-cancer therapy, with the exception of alopecia that has not resolved to Grade ≤ 1 within 7 days prior to start of emavusertib",
                    "criterion": "acute or chronic toxicity from prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "alopecia that has not resolved to Grade ≤ 1 within 7 days prior to start of emavusertib"
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of any acute or chronic non-hematological toxicity ≥ Grade 3 at Screening, or prior to start of emavusertib must resolve to ≤ Grade 2",
                    "criterion": "acute or chronic non-hematological toxicity",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "resolution",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}